Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors in the central nervous process, conolidine modulates alternate molecular targets. A Science Improvements review found that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://maries343rwu6.blogunok.com/profile